Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
arcticnovartis
- Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1
- Clinically meaningful improvements of protein in urine observed as early as two weeks, with sustained reduction over treatment period1
- Fabhalta targets the alternative complement pathway; activation is a key driver of inflammation associated with IgAN2-4